Medical complications of lung transplantation

Proceedings of the American Thoracic Society

Volumn 6, Issue 1, 2009, Pages 101-107

  Lyu, Dennis M ^a,b   Zamora, Martin R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE   (United States)

Author keywords

Lung transplantation; Medical complications

Indexed keywords

ACICLOVIR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCITRIOL; CALCIUM; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ESTROGEN; GLUCOCORTICOID; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; IRON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; RITUXIMAB; STEROID; TACROLIMUS; UNINDEXED DRUG; VALGANCICLOVIR; VITAMIN D;

ANEMIA; ATHEROSCLEROSIS; AVASCULAR NECROSIS; BLINDNESS; BRAIN DISEASE; BRAIN EDEMA; BRONCHIOLITIS OBLITERANS; CANCER RISK; CONFUSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOPENIA; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESTROGEN THERAPY; FOCAL GLOMERULONEPHRITIS; FOOT SEIZURE; GASTROINTESTINAL DISEASE; HAND SEIZURE; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IRON DEFICIENCY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LUNG EMBOLISM; LUNG TOXICITY; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NAUSEA; NEOPLASM; NEUROLOGICAL COMPLICATION; OSTEOPENIA; OSTEOPOROSIS; PARESTHESIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE THROMBOSIS; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; RESPIRATORY TRACT DISEASE; REVIEW; SEIZURE; SKIN CANCER; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUNG TRANSPLANTATION; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK FACTORS;

EID: 58549115473     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200808-077GO     Document Type: Review

References (122)

1. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999;340:1081-1091.
2. Trulock EP, Christie JD, Edwards LB, Boucek MM, Aurora P, Taylor DO, Dobbels F, Rahmel AO, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007;26:782-795.
3. Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002;61:2228-2234.
4. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
5. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006;6:671-679.
6. Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007;18:3031-3041.
7. Goes NB, Colvin RB. Case records of the Massachusetts General Hospital. Case 12-2007: a 56-year-old woman with renal failure after heart-lung transplantation. N Engl J Med 2007;356:1657-1665.
8. Nizze H, Mihatsch MJ, Zollinger HU, Brocheriou C, Gokel JM, Henry K, Sloane JP, Stovin PG. Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants. Clin Nephrol 1988;30:248-260.
9. Esposito C, De Mauri A, Vitulo P, Oggionni T, Cornacchia F, Valentino R, Grosjean F, Torreggiani M, Dal Canton A. Risk factors for chronic renal dysfunction in lung transplant recipients. Transplantation 2007;84:1701-1703.
10. Elliott WJ, Murphy MB, Karp R. Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic. J Heart Lung Transplant 1991;10:373-379.
11. Lin J, Valeri AM, Markowitz GS, D'Agati VD, Cohen DJ, Radhakrishnan J. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002;73:783-788.
12. Venuta F, De Giacomo T, Rendina EA, Quattrucci S, Mercadante E, Cimino G, Ibrahim M, Diso D, Bachetoni A, Coloni GF. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg 2004;78:1940-1943.
13. Groetzner J, Kaczmarek I, Meiser B, Müller M, Daebritz S, Reichart B. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004;77:568-574.
14. Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M. Patterns of pulmonary complications associated with sirolimus. Respiration 2006;73:367-374.
15. Groetzner J, Kur F, Spelsberg F, Behr J, Frey L, Bittmann I, Vogeser M, Ueberfuhr P, Meiser B, Hatz R, et al.; Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004;23:632-638.
16. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, Trulock EP. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation 2004;77:431-437.
17. Milstone A, Vilchez RA, Geiger X, Fogo AB, Butel JS, Dummer S. Polyomavirus simian virus 40 infection associated with nephropathy in a lung-transplant recipient. Transplantation 2004;77:1019-1024.
18. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-185.
19. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002;25:583-592.
20. Mazali FC, Lalli CA, Alves-Filho G, Mazzali M. Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc 2008;40:764-766.
21. Ollech JE, Kramer MR, Peled N, Ollech A, Amital A, Medalion B, Saute M, Shitrit D. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. Eur J Cardiothorac Surg 2008;33:844-848.
22. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, Friedman EA. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998;65:380-384.
23. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67:2415-2421.
24. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005;19:291-298.
25. Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003;167:1271-1278.
26. Fessler MB, Young SK, Jeyaseelan S, Lieber JG, Arndt PG, Nick JA, Worthen GS. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005;171:606-615.
27. Morimoto K, Janssen WJ, Fessler MB, McPhillips KA, Borges VM, Bowler RP, Xiao YQ, Kench JA, Henson PM, Vandivier RW. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006;176:7657-7665.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
29. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005;90:2456-2465.
30. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003;14:617-630.
31. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
32. Shane E, Silverberg SJ, Donovan D, Papadopoulos A, Staron RB, Addesso V, Jorgesen B, McGregor C, Schulman L. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 1996;101:262-269.
33. Stephenson A, Jamal S, Dowdell T, Pearce D, Corey M, Tullis E. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest 2006;130:539-544.
34. Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax 1993;48:589-593.
35. Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest 1996;109:1176-1183.
36. Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest 2000;117:476-481.
37. Shane E, Papadopoulos A, Staron RB, Addesso V, Donovan D, McGregor C, Schulman LL. Bone loss and fracture after lung transplantation. Transplantation 1999;68:220-227.
38. Ferrari SL, Nicod LP, Hamacher J, Spiliopoulos A, Slosman DO, Rochat T, Bonjour JP, Rizzoli R. Osteoporosis in patients undergoing lung transplantation. Eur Respir J 1996;9:2378-2382.
39. Vedi S, Greer S, Skingle SJ, Garrahan NJ, Ninkovic M, Alexander GA, Compston JE. Mechanism of bone loss after liver transplantation: a histomorphometric analysis. J Bone Miner Res 1999;14:281-287.
40. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991;325:544-550.
41. McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Sheil AG, Evans RA, McCaughan GW. Bone loss after liver transplantation. Hepatology 1991;14:613-619.
42. Cahill BC, O'Rourke MK, Parker S, Stringham JC, Karwande SV, Knecht TP. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation 2001;72:1251-1255.
43. Braith RW, Mills RM, Welsch MA, Keller JW, Pollock ML. Resistance exercise training restores bone mineral density in heart transplant recipients. J Am Coll Cardiol 1996;28:1471-1477.
44. Snavely NR, Sonabend M, Rosen T. Posttransplant Epstein-Barr virus related lymphoproliferative disorder with a primary cutaneous presentation. Dermatol Online J 2007;13:7.
45. Isoniemi H, Appelberg J, Nilsson C, Mäkelä P, Risteli J, Höckerstedt K. Transdermal estrogen therapy improves lipid profile and osteoporosis in postmenopausal liver transplant patients. Transplant Proc 2001;33:1472-1473.
46. Stempfle HU, Werner C, Echtler S, Wehr U, Rambeck WA, Siebert U, Uberfuhr P, Angermann CE, Theisen K, Gärtner R. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 1999;68:523-530.
47. Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000;15:1818-1824.
48. Henderson K, Eisman J, Keogh A, MacDonald P, Glanville A, Spratt P, Sambrook P. Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 2001;16:565-571.
49. Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 2000;19:736-743.
50. Shane E, Rodino MA, McMahon DJ, Addesso V, Staron RB, Seibel MJ, Mancini D, Michler RE, Lo SH. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 1998;17:1089-1096.
51. Ebeling PR. Transplantation osteoporosis. Curr Osteoporos Rep 2007;5:29-37.
52. Marston SB, Gillingham K, Bailey RF, Cheng EY. Osteonecrosis of the femoral head after solid organ transplantation: a prospective study. J Bone Joint Surg Am 2002;84-A:2145-2151.
53. Kopecky KK, Braunstein EM, Brandt KD, Filo RS, Leapman SB, Capello WN, Klatte EC. Apparent avascular necrosis of the hip: appearance and spontaneous resolution of MR findings in renal allograft recipients. Radiology 1991;179:523-527.
54. Schoch OD, Speich R, Schmid C, Tschopp O, Russi EW, Weder W, Boehler A. Osteonecrosis after lung transplantation: cystic fibrosis as a potential risk factor. Transplantation 2000;69:1629-1632.
55. Clinkscales A, Cleary JD. Steroid-induced avascular necrosis. Ann Pharmacother 2002;36:1105.
56. Frost AE, Keller CA. Anemia and erythropoietin levels in recipients of solid organ transplants. The Multi-Organ Transplant Group. Transplantation 1993;56:1008-1011.
57. Hunt BJ, Amin S, Halil O, Yacoub M. The prevalence, course, and characteristics of chronic anemia after heart and lung transplantation. Transplantation 1992;53:1251-1256.
58. End A, Stift A, Wieselthaler G, Griesmacher A, Schlechta B, Koppensteiner R, Schreiner W, Geissler K, Stockenhuber F, Klepetko W. Anemia and erythropoietin levels in lung transplant recipients. Transplantation 1995;60:1245-1251.
59. End A, Stift A, Ringl H, Inhauser T, Grimm M, Geissler K, Stockenhuber F, Klepetko W. The use of recombinant human erythropoietin in lung transplantation. Wien Klin Wochenschr 1995;107:181-183.
60. Kariyawasam HH, Gyi KM, Hodson ME, Cohen BJ. Anaemia in lung transplant patient caused by parvovirus B19. Thorax 2000;55:619-620.
61. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004;4:1219-1226.
62. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, Cohen JI, Young NS, John Barrett A. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007;109:3219-3224.
63. Salerno CT, Burdine J, Perry EH, Kshettry VR, Hertz MI, Bolman RM 3rd. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation. Transplantation 1998;65:261-264.
64. Taaning E, Morling N, Mortensen SA, Pettersson G, Simonsen AC. Severe hemolysis caused by graft-derived anti-B production after lung transplantation. J Heart Lung Transplant 1996;15:850-851.
65. Riechsteiner G, Speich R, Schanz U, Russi EW, Weder W, Boehler A. Haemolytic anaemia after lung transplantation: an immune-mediated phenomenon? Swiss Med Wkly 2003;133:143-147.
66. Hachem RR, Yusen RD, Chakinala MM, Aloush AA, Patterson GA, Trulock EP. Thrombotic microangiopathy after lung transplantation. Transplantation 2006;81:57-63.
67. Luckraz H, Zagolin M, McNeil K, Wallwork J. Graft-versus-host disease in lung transplantation: 4 case reports and literature review. J Heart Lung Transplant 2003;22:691-697.
68. Kroshus TJ, Kshettry VR, Hertz MI, Bolman RM 3rd. Deep venous thrombosis and pulmonary embolism after lung transplantation. J Thorac Cardiovasc Surg 1995;110:540-544.
69. Izbicki G, Bairey O, Shitrit D, Lahav J, Kramer MR. Increased thromboembolic events after lung transplantation. Chest 2006;129:412-416.
70. Burns KE, Iacono AT. Incidence of clinically unsuspected pulmonary embolism in mechanically ventilated lung transplant recipients. Transplantation 2003;76:964-968.
71. Burns KE, Iacono AT. Pulmonary embolism on postmortem examination: an under-recognized complication in lung-transplant recipients? Transplantation 2004;77:692-698.
72. Nathan SD, Barnett SD, Urban BA, Nowalk C, Moran BR, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest 2003;123:1758-1763.
73. Yegen HA, Lederer DJ, Barr RG, Wilt JS, Fang Y, Bagiella E, D'Ovidio F, Okun JM, Sonett JR, Arcasoy SM, Kawut SM. Risk factors for venous thromboembolism after lung transplantation. Chest 2007;132:547-553.
74. Brunkwall J, Bergqvist D, Bergentz SE, Bornmyr S, Husberg B. Postoperative deep venous thrombosis after renal transplantation. Effects of cyclosporine. Transplantation 1987;43:647-649.
75. Allen RD, Michie CA, Murie JA, Morris PJ. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987;164:137-142.
76. Humar A, Johnson EM, Gillingham KJ, Sutherland DE, Payne WD, Dunn DL, Wrenshall LE, Najarian JS, Gruessner RW, Matas AJ. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation 1998;65:229-234.
77. Kahan ES, Petersen G, Gaughan JP, Criner GJ. High incidence of venous thromboembolic events in lung transplant recipients. J Heart Lung Transplant 2007;26:339-344.
78. Davis RD Jr, Lau CL, Eubanks S, Messier RH, Hadjiliadis D, Steele MP, Palmer SM. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003;125:533-542.
79. Beaver TM, Fullerton DA, Zamora MR, Badesch DB, Weill D, Brown JM, Campbell DN, Grover FL. Colon perforation after lung transplantation. Ann Thorac Surg 1996;62:839-843.
80. Goldberg HJ, Hertz MI, Ricciardi R, Madoff RD, Baxter NN, Bullard KM. Colon and rectal complications after heart and lung transplantation. J Am Coll Surg 2006;202:55-61.
81. Bravo C, Gispert P, Borro JM, de la Torre M, Cifrián Martínez JM, Fernández Rozas S, Zurbano Goñi F; MITOS Study Group. Prevalence and management of gastrointestinal complications in lung transplant patients: MITOS study group. Transplant Proc 2007;39:2409-2412.
82. Berkowitz N, Schulman LL, McGregor C, Markowitz D. Gastroparesis after lung transplantation: potential role in postoperative respiratory complications. Chest 1995;108:1602-1607.
83. Young LR, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003;124:1689-1693.
84. Hadjiliadis D, Duane Davis R, Steele MP, Messier RH, Lau CL, Eubanks SS, Palmer SM. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 2003;17:363-368.
85. Cantu E III, Appel JZ 3rd, Hartwig MG, Woreta H, Green C, Messier R, Palmer SM, Davis RD Jr. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004;78:1142-1151.
86. Gilljam M, Chaparro C, Tullis E, Chan C, Keshavjee S, Hutcheon M. GI complications after lung transplantation in patients with cystic fibrosis. Chest 2003;123:37-41.
87. Goldstein LS, Haug MT 3rd, Perl J 2nd, Perl MK, Maurer JR, Arroliga AC, Mehta AC, Kirby T, Higgins B, Stillwell PC. Central nervous system complications after lung transplantation. J Heart Lung Transplant 1998;17:185-191.
88. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-1738.
89. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
90. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80(2, Suppl)S254-S264.
91. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993;12:S328-S336.
92. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000;23:101-113.
93. Amital A, Shitrit D, Raviv Y, Bendayan D, Sahar G, Bakal I, Kramer MR. Development of malignancy following lung transplantation. Transplantation 2006;81:547-551.
94. Anile M, Venuta F, Diso D, De Giacomo T, Rendina EA, Rolla M, Ruberto F, Liparulo V, Aratari MT, Di Stasio M, et al. Malignancies following lung transplantation. Transplant Proc 2007;39:1983-1984.
95. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, et al.; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:745-755.
96. Arcasoy SM, Wilt J. Medical complications after lung transplantation. Semin Respir Crit Care Med 2006;27:508-520.
97. Chadburn A, Cesarman E, Knowles DM. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997;14:15-26.
98. Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001;3:88-96.
99. Nalesnik MA. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 1998;20:325-342.
100. Ramalingam P, Rybicki L, Smith MD, Abrahams NA, Tubbs RR, Pettay J, Farver CF, Hsi ED. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 2002;15:647-656.
101. Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003;124:1242-1249.
102. Gao SZ, Chaparro SV, Perlroth M, Montoya JG, Miller JL, DiMiceli S, Hastie T, Oyer PE, Schroeder J. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003;22:505-514.
103. Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, Palevsky H, Pietra GG, Tomaszewski JE. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996;119:544-551.
104. Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M, Hardesty RL, Dummer JS. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991;10:877-886.
105. Siegel MJ, Lee EY, Sweet SC, Hildebolt C. CT of posttransplantation lymphoproliferative disorder in pediatric recipients of lung allograft. AJR Am J Roentgenol 2003;181:1125-1131.
106. Wigle DA, Chaparro C, Humar A, Hutcheon MA, Chan CK, Keshavjee S. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001;72:1783-1786.
107. Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001;20:1054-1063.
108. Yousem SA, Randhawa P, Locker J, Paradis IL, Dauber JA, Griffith BP, Nalesnik MA. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft. Hum Pathol 1989;20:361-369.
109. Hsi ED, Singleton TP, Swinnen L, Dunphy CH, Alkan S. Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol 2000;24:100-106.
110. McFarlane R, Hurst S, Sabath D, George E, Argenyi Z. A rare case of plasmacytoma-like post-transplant lymphoproliferative disorder presenting in the skin of a lung transplant patient. J Cutan Pathol 2008;35:599-602.
111. Ho M. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc 1995;27:38-40.
112. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-565.
113. Ho M, Miller G, Atchison RW, Breinig MK, Dummer JS, Andiman W, Starzl TE, Eastman R, Griffith BP, Hardesty RL. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985;152:876-886.
114. Tsai DE, Douglas L, Andreadis C, Vogl DT, Arnoldi S, Kotloff R, Svoboda J, Bloom RD, Olthoff KM, Brozena SC, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008;8:1016-1024.
115. Lewin KJ. Post-transplant lymphoproliferative disorders. Pathol Oncol Res 1997;3:177-182.
116. Verschuuren E, van der Bij W, de Boer W, Timens W, Middeldorp J, The TH. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. J Med Virol 2003;69:258-266.
117. Kemnitz J, Cremer J, Gebel M, Uysal A, Haverich A, Georgii A. T-cell lymphoma after heart transplantation. Am J Clin Pathol 1990;94:95-101.
118. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995;14:214-221.
119. Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996;154:1712-1717.
120. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005;104:1661-1667.
121. Knoop C, Kentos A, Remmelink M, Garbar C, Goldman S, Feremans W, Estenne M. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. Clin Transplant 2006;20:179-187.
122. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-492.